A general inefficacy interim monitoring rule for randomized clinical trials

Clinical Trials

Volumn 7, Issue 3, 2010, Pages 197-208

  Freidlin, Boris ^a   Korn, Edward L ^a   Gray, Robert ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE HYPOTHESIS; ARTICLE; CLINICAL STUDY; EVIDENCE BASED PRACTICE; HEALTH CARE UTILIZATION; INFORMATION DISSEMINATION; INTERMETHOD COMPARISON; MEDICAL INFORMATION; NULL HYPOTHESIS; POWER ANALYSIS; PRIORITY JOURNAL; PROCESS MODEL; PROCESS MONITORING; STUDY DESIGN; TREATMENT WITHDRAWAL;

ALGORITHMS; CLINICAL TRIALS, PHASE III AS TOPIC; EFFICIENCY; ENDPOINT DETERMINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77952760568     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510369019     Document Type: Article

References (36)

1. Ellenberg SS, Fleming TR, DeMets DL Data Monitoring Committees in Clinical trials. Willey, Chichester, 2002.
2. Ware JH, Muller JE, Braunwald E. The futility index. Am J Med 1985 ; 78: 635-643.
3. Freidlin B., Korn EL A comment on futility monitoring. Control Clin Trials 2002 ; 23: 355-366.
4. Freidlin B., Korn EL Monitoring for lack of benefit: a critical component of a randomized clinical trial. J Clin Oncol 2009 ; 27: 629-633.
5. Whitehead J., Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983 ; 39: 227-236.
6. Emerson SS, Fleming TR Symmetric group sequential test designs. Biometrics 1989 ; 45: 905-923.
7. Pampallona S., Tsiatis AA Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J Stat Plan Inf 1994 ; 42: 19-35.
8. European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials with flexible design and analysis plan. Available at: http://www.emea.europa.eu/pdfs/human/ewp/245902enadopted.pdf (accessed 26 March 2010 ).
9. Snapinn S., Chen MG, Jiang Q., et al. Assessment of futility in clinical trials. Pharm Stat 2006 ; 5: 273-281.
10. Cook TD, DeMets DL Introduction to Statistical Methods for Clinical Trials. Chapman & Hall/CRC, Boca Raton, 2008.
11. Pocock SJ When to stop a clinical trial. BMJ 1992 ; 305: 235-240.
12. OBrien PC, Fleming TR A multiple testing procedure for clinical trials. Biometrics 1979 ; 35: 549-556.
13. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 ; 351: 1513-1520.
14. Williamson SK, Crowley JJ, Lara PN, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005 ; 23: 9097-9104.
15. Lara Jr PN, Natale R., Crowley J., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009 ; 27: 2530-2535.
16. Jennison C., Turnbull BW Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall/CRC, Boca Raton, 2000.
17. Stadtmauer EA, ONeill A., Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000 ; 342: 1069-1076.
18. Sandler A., Gray R., Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 ; 355: 2542-2550.
19. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 ; 25: 1539-1544.
20. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 ; 357: 2666-2676.
21. Lan KKG, Simon R., Halperin M. Stochastically curtailed tests in long-term clinical trials. Commu Statist C 1982 ; 1: 207-219.
22. Demets DL Futility approaches to interim monitoring by data monitoring committees. Clin Trials 2006 ; 3: 522-529.
23. Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics 1988 ; 44: 579-585.
24. Evans SR, Li L., Wei LJ Data monitoring in clinical trials using prediction. Drug Inform J 2007 ; 41: 733-742.
25. Lachin JM Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. Clin Trials 2009 ; 6: 565-573.
26. Teerlink JR, McMurray JJ, Bourge RC, et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005 ; 150: 46-53.
27. The TRIUMPH Investigators. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007 ; 297: 1657-1666.
28. Spriggs DR, Brady MF, Vaccarello L., et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007 ; 25: 4466-4471.
29. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009 ; 361: 2209-2220.
30. Spiegelhalter DJ, Freedman LS, Blackburn PR Monitoring clinical trials: conditional or predictive power? Control Clin Trials 1986 ; 7: 8-17.
31. Dignam JJ, Bryant J., Wieand HS, et al. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials 1998 ; 19: 575-588.
32. Ellenberg SS, Eisenberger MA An efficient design for phase III studies of combination chemotherapies. Cancer Treat Rep 1985 ; 69: 1147-1152.
33. Wieand S., Schroeder G., OFallon JR Stopping when the experimental regimen does not appear to help. Stat Med 1994 ; 13: 1453-1458.
34. Vergote I., Finkler N., Del Campo J., et al. Single agent canfosfamide vs pegylated liposomal doxorubicin or topotecan 3rd-line treatment of platinum refractory or resitant ovarian cancer. 2007; Annual Meeting of the American Society of Clinical Oncology, Abstract LBA5528.
35. Haybittle JL Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971 ; 44: 793-797.
36. Korn EL, Freidlin B., Mooney M. Stopping or reporting early for positive results in randomized clinical trials: the NCI Cooperative Group Experience 1990-2005. J Clin Oncol 2009 ; 27: 1543-1544.